Antisense Therapeutics Shares rise on long COVID-19 study
- Antisense Therapeutics (ANP) announces the outcomes of its collaboration to study the neurological aspects of long COVID-19 in patients who hadn’t been hospitalised
- Blood samples were collected and used to generate data on up to 7000 proteins in the blood using the proteomics protein analysis
- Data identified a number of proteins that can be used as diagnostic markers which could help identify neuro long COVID patients for better designed clinical trials
- Antisense plans to review new patent applications in the US with targeted pharmaceutical and diagnostic companies for potential commercial discussions
- ANP shares are up 18.2 per cent on the market to trade at 13 cents as of 1:42 pm AEST
